Cost/Benefit Analysis of Case Management Policies in a DUI Lab

摘要

A study was previously conducted and published describing the magnitude of the under-reporting of drugs in driving under the influence (DUI) cases by using a blood drug screen (BDS) case management protocol and to determine whether not reporting those drugs would have a meaningful impact on the DUI cases. A follow-up study presented herein was conducted to generate a larger dataset for evaluation and to compare the results to the original study. For this follow-up study of 576 cases, the laboratory BDS protocol was modified so that a BDS was performed for all felony cases and all misdemeanor cases with a BAC 0.08 g/dL, the drugs detected are not significant for supporting a DUI and do not warrant the substantial increase in analysis cost and time required.